drugset / Trial / NCT06258330
Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1, first-in-human study to assess the safety and tolerability of AM003 in patients with locally advanced and metastatic solid tumors
Timeline
- Start
- 2022-06-22
- Primary completion
- 2024-07-07
- Completion
- 2024-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AM003 | Aptamer | 34 mg | Other |
| Subject | AM003 | Aptamer | 68 mg | Other |
| Subject | AM003 | Aptamer | 136 mg | Other |